Cognition Therapeutics files investor presentation on Phase 2 SHINE results for CT1812 Alzheimer's study

COGNITION THERAPEUTICS INC

Phase 2 proof-of-concept SHINE study of CT1812 in mild-to-moderate Alzheimer's disease.
Results presented on July 29, 2024 via investor presentation filed as exhibit.
No specific efficacy or safety endpoints disclosed in the 8-K filing text.

item 8.01 item 9.01

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-083280

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.